
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Richard Adler, MD, shares the methods his practice has used to implement intense pulsed light (IPL) therapy into their patient base, while attending the 2019 American Academy of Ophthalmology's annual meeting in San Francisco.



